Northern Trust’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Northern Trust’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,235	Closed	-$45.4K	–	4553
2023 Q4	$45.4K	Hold	4,235	–	–	﹤0.01%	4252
2023 Q3	$25.4K	Hold	4,235	–	–	﹤0.01%	4291
2023 Q2	$29.2K	Hold	4,235	–	–	﹤0.01%	4334
2023 Q1	$66.5K	Buy	4,235 +140	+3%	+$2.75K	﹤0.01%	4189
2022 Q4	$81.9K	Hold	4,095	–	–	﹤0.01%	4157
2022 Q3	$73K	Hold	4,095	–	–	﹤0.01%	4217
2022 Q2	$91K	Sell	4,095 -14,582	-78%	-$325K	﹤0.01%	4212
2022 Q1	$519K	Sell	18,677 -1,152	-6%	-$41.9K	﹤0.01%	3726
2021 Q4	$900K	Sell	19,829 -8,623	-30%	-$580K	﹤0.01%	3587
2021 Q3	$2.37M	Sell	28,452 -1,030	-3%	-$85.2K	﹤0.01%	3195
2021 Q2	$2.8M	Buy	29,482 +25,259	+598%	+$3M	﹤0.01%	3192
2021 Q1	$703K	Buy	4,223 +2,006	+90%	+$265K	﹤0.01%	3717
2020 Q4	$217K	Buy	2,217 +1,459	+192%	+$92.3K	﹤0.01%	3941
2020 Q3	$26K	Buy	758 +65	+9%	+$3.19K	﹤0.01%	4182
2020 Q2	$40K	Buy	693 +14	+2%	+$790	﹤0.01%	4083
2020 Q1	$40K	Hold	679	–	–	﹤0.01%	3989
2019 Q4	$54K	Buy	+679	New	+$70.3K	﹤0.01%	4047
2019 Q3	–	Sell	-555	Closed	-$73K	–	4302
2019 Q2	$73K	Sell	555 -30	-5%	-$4.63K	﹤0.01%	4020
2019 Q1	$98K	Sell	585 -12	-2%	-$1.79K	﹤0.01%	3927
2018 Q4	$65K	Buy	597 +3	+0.5%	+$600	﹤0.01%	4005
2018 Q3	$130K	Buy	594 +163	+38%	+$391K	﹤0.01%	3974
2018 Q2	$923K	Buy	431 +297	+222%	+$753K	﹤0.01%	3472
2018 Q1	$332K	Buy	134 +26	+24%	+$57.9K	﹤0.01%	3678
2017 Q4	$192K	Buy	108 +32	+42%	+$46.3K	﹤0.01%	3828
2017 Q3	$90K	Hold	76	–	–	﹤0.01%	3977
2017 Q2	$56K	Buy	76 +2	+3%	+$1.23K	﹤0.01%	4066
2017 Q1	$51K	Buy	+74	New	+$54.2K	﹤0.01%	4054
2016 Q4	–	Sell	-50	Closed	-$54K	–	4213
2016 Q3	$54K	Hold	50	–	–	﹤0.01%	3994
2016 Q2	$38K	Hold	50	–	–	﹤0.01%	4053
2016 Q1	$35K	Hold	50	–	–	﹤0.01%	4071
2015 Q4	$49K	Hold	50	–	–	﹤0.01%	4049
2015 Q3	$53K	Buy	50 +3	+6%	+$4.38K	﹤0.01%	4059
2015 Q2	$97K	Sell	47 -6	-11%	-$8.53K	﹤0.01%	3957
2015 Q1	$50K	Sell	53 -1	-2%	-$994	﹤0.01%	4153
2014 Q4	$55K	Hold	54	–	–	﹤0.01%	4079
2014 Q3	$55K	Sell	54 -150	-74%	-$221K	﹤0.01%	4130
2014 Q2	$394K	Sell	204 -52	-20%	-$103K	﹤0.01%	3668
2014 Q1	$548K	Sell	256 -24	-9%	-$59.8K	﹤0.01%	3533
2013 Q4	$646K	Buy	280 +3	+1%	+$6.86K	﹤0.01%	3465
2013 Q3	$787K	Sell	277 -20	-7%	-$99.5K	﹤0.01%	3381
2013 Q2	$2.75M	Buy	+297	New	+$2.29M	﹤0.01%	2788

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust's ONCT Position: Q1 2024 in Review

Northern Trust sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 4,235 shares — an estimated $45.4K sold.

Northern Trust first reported a position in ONCT in Q2 2013 and held it in 41 quarters. The position peaked at $2.8M in Q2 2021. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

Northern Trust reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Northern Trust sold 4,235 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $45.4K.
Northern Trust first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 41 quarters.
Northern Trust's Oncternal Therapeutics, Inc. Common Stock position peaked at $2.8M in Q2 2021.
24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Northern Trust's 13F filing for Q1 2024, filed 14 May 2024.